Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Valiant LaboratoriesNSE:VALIANTLAB +4.93%53 3-Year Book Growth Rate is 38.70% as of Jun. 2026, which is 0% below its 10-year median of 38.80. GuruFocus rates NSE:VALIANTLAB with a GF Score™ of 53/100 and a GF Value™ of ₹149.14 (Modestly Undervalued). The stock has 7 warning signs investors should review. Among 908 Drug Manufacturers companies, Valiant Laboratories ranks better than 93.61% on this metric.
During the past 12 months, Valiant Laboratories's average Book Value per Share Growth Rate was 14.40% per year.
During the past 3 years, the average Book Value per Share Growth Rate was 38.70% per year.
During the past 5 years, the average Book Value per Share Growth Rate was 32.90% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.
During the past 6 years, the highest 3-Year average Book Value per Share Growth Rate of Valiant Laboratories was 48.60% per year. The lowest was 38.70% per year. And the median was 38.80% per year.
Valiant Laboratories (NSE:VALIANTLAB) 3-Year Book Growth Rate Explanation
Book Value per Share is the ratio of equity available to common shareholders divided by the shares outstanding. Book value per share effectively indicates a firm's net asset value on a per-share basis. It can be used by investors to gauge whether a stock price is undervalued by comparing it to the firm's market value per share. Theoretically, it is what the shareholders will receive if the company is liquidated.
Valiant Laboratories 3-Year Book Growth Rate Related Terms
NSE:VALIANTLAB vs ZTS: 3-Year Book Growth Rate Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Valiant Laboratories's 3-Year Book Growth Rate, along with its competitors' market caps and 3-Year Book Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Valiant Laboratories 3-Year Book Growth Rate vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Valiant Laboratories's 3-Year Book Growth Rate distribution charts can be found below:
* The bar in red indicates where Valiant Laboratories's 3-Year Book Growth Rate falls into.
Valiant Laboratories 3-Year Book Growth Rate Calculation
This is the 3-year average growth rate of Book Value per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.
What does a 3-Year Book Growth Rate of 38.70% mean?
Valiant Laboratories (NSE:VALIANTLAB) has a 3-Year Book Growth Rate of 38.70% as of Jun. 2026. 3-Year Book Growth Rate is the 3-year average growth rate of Book Value per Share. View historical data for Valiant Laboratories and its competitors. This is near median its historical median of 38.80. Over the past decade, Valiant Laboratories' 3-Year Book Growth Rate has ranged from 38.70 to 48.60. According to the industry distribution chart, Valiant Laboratories ranks #58 out of 908 companies in the Drug Manufacturers industry, placing it in the top 6.4%.
Is Valiant Laboratories' 3-Year Book Growth Rate too high?
Valiant Laboratories' current 3-Year Book Growth Rate of 38.70% is near median its 10-year median of 38.80. Over the past 10 years, this metric has ranged from a low of 38.70 to a high of 48.60. The Drug Manufacturers industry median 3-Year Book Growth Rate is 4.60. Valiant Laboratories' value of 38.70% is 741.3% above this industry median. Based on the distribution chart, Valiant Laboratories ranks #58 out of 908 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Valiant Laboratories has a GF Score™ of 53/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Valiant Laboratories' 3-Year Book Growth Rate compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Valiant Laboratories ranks #58 out of 908 companies for 3-Year Book Growth Rate. This places Valiant Laboratories in the top 6% of its industry — outperforming the majority of peers. The industry median 3-Year Book Growth Rate is 4.60. Valiant Laboratories' value of 38.70% is 741.3% above this benchmark. Historically, Valiant Laboratories' own 3-Year Book Growth Rate has ranged from 38.70 to 48.60 over the past decade. While the company's 10-year median is 38.80 vs. the industry median of 4.60, Valiant Laboratories has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year Book Growth Rate for a Drug Manufacturers company?
The median 3-Year Book Growth Rate among Drug Manufacturers companies is 4.60, based on 908 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year Book Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year Book Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Valiant Laboratories's current 3-Year Book Growth Rate of 38.70% is 741.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year Book Growth Rate mean?
A high 3-Year Book Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year Book Growth Rate is the 3-year average growth rate of Book Value per Share. View historical data for Valiant Laboratories and its competitors. For the Drug Manufacturers industry, the median 3-Year Book Growth Rate is 4.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Valiant Laboratories's current 3-Year Book Growth Rate is 38.70%, which is near median its own 10-year median of 38.80. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Valiant Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Valiant Laboratories (NSE:VALIANTLAB) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹149.14, compared to a current price of ₹105.48 — trading 29.3% below its estimated fair value. The current 3-Year Book Growth Rate is 38.70%, which is near median its 10-year median of 38.80 and 741.3% above the Drug Manufacturers industry median of 4.60. Valiant Laboratories' overall GF Score™ is 53/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year Book Growth Rate calculated?
3-Year Book Growth Rate is calculated from a company's financial statements. For Valiant Laboratories (NSE:VALIANTLAB), the current 3-Year Book Growth Rate is 38.70% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Valiant Laboratories (NSE:VALIANTLAB) Overvalued in 2026?
Based on GuruFocus' analysis, Valiant Laboratories stock appears to be undervalued.
The current stock price of ₹105.48 is trading 29.3% below its estimated GF Value™ of ₹149.14.
GuruFocus considers Valiant Laboratories to be Modestly Undervalued.
Key valuation signals for NSE:VALIANTLAB:
3-Year Book Growth Rate: 38.70% (near median its 10-year median of 38.80)
GF Value™: ₹149.14 vs. price of ₹105.48 (29.3% below fair value)
Industry Position: 741.3% above the Drug Manufacturers median (#58 of 908)
No single metric tells the full story. See the NSE:VALIANTLAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Valiant Laboratories Ltd is an Active Pharmaceutical Ingredient (API)/Bulk Drug manufacturing company with having focus on manufacturing Paracetamol. Paracetamol is one of the widely used analgesics globally and is recommended as the first-line therapy in pain conditions by the World Health Organization. Paracetamol has several applications such as usage in the treatment of headaches, muscle aches, arthritis, backaches, toothaches, colds, and fever. It manufactures Paracetamol in various grades such as IP/BP/EP/USP, as per the pharmacopeia requirements of its customers.
53GF Score
Get the complete analysis for NSE:VALIANTLAB
3-Year Book Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:VALIANTLAB has been successfully added to your 
